Researcher

Linong Ji

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

AUG 14, 2026 · JOURNAL ARTICLE

Oral nonpeptide GLP-1 receptor agonist VCT220 for obesity treatment: a randomized, double-blind, phase II trial

Signal Transduction and Targeted Therapy

Phase II RCT with clear dose-dependent weight loss versus placebo and metabolic benefits, but limited to 16 weeks and requiring Phase III confirmation before clinical adoption.

PromisingPharmacology and Obesity Treatment Chao Meng Xianghua Zhang

Reported

Primary endpoint: mean body weigh…−5.75%

Primary endpoint: mean body weigh…−9.73%

Primary endpoint: mean body weigh…−1.61%

AUG 14, 2026 · JOURNAL ARTICLE

Survodutide for Obesity in Chinese Adults: Phase 3 Randomized Trial Design and Baseline Characteristics (SYNCHRONIZE™-CN)

Diabetes Therapy

This is a design and baseline characteristics report of an ongoing Phase 3 trial with no efficacy or safety results reported; it describes the study protocol and enrolled population but cannot yet support clinical claims.

PreliminaryPharmacology and Obesity Treatment Isabel M. Kloer Liming Chen

Reported

Sample size306

Mean age at baseline36.9 years

Mean body weight at baseline93.9 kg